Voya Investment Management LLC increased its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) by 2.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 412,814 shares of the company’s stock after buying an additional 11,665 shares during the period. Voya Investment Management LLC’s holdings in Oruka Therapeutics were worth $34,383,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Oruka Therapeutics during the second quarter worth approximately $474,916,000. Jupiter Topco LLC purchased a new position in Oruka Therapeutics in the 2nd quarter worth approximately $130,968,000. Bank of America Corp DE acquired a new position in Oruka Therapeutics in the 2nd quarter worth $33,578,000. Braidwell LP purchased a new position in Oruka Therapeutics in the second quarter valued at about $26,473,000. Finally, Atika Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 1st quarter valued at approximately $11,277,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently commented on ORKA. BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 10th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Jefferies Financial Group set a $133.00 price target on Oruka Therapeutics and gave the company a “buy” rating in a research report on Thursday. Finally, Wedbush reissued an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $141.00.
View Our Latest Research Report on ORKA
Insider Activity at Oruka Therapeutics
In related news, CEO Lawrence Klein sold 75,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $104.97, for a total value of $1,049,700.00. Following the completion of the transaction, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,492,568.43. The trade was a 41.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 197,950 shares of company stock worth $18,288,360. 23.49% of the stock is owned by insiders.
Oruka Therapeutics Stock Up 1.9%
ORKA opened at $97.57 on Friday. Oruka Therapeutics, Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $115.51. The business has a 50-day moving average of $90.05 and a 200-day moving average of $73.61.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.
About Oruka Therapeutics
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report).
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
